Enobia Adds $40M for Hypophosphatasia ERT
By Jennifer Boggs
Thursday, August 11, 2011
Montreal-based Enobia Pharma Inc. padded its coffers via a $40 million private placement to support ongoing work on ENB-0040, an enzyme replacement therapy for rare genetic bone disorder hypophosphatasia (HPP).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.